A 25-year-old man has had right knee pain with “popping and catching” for the past 2 years. On examination, there is a reduced range of motion at the right knee, but no tenderness or swelling. MR imaging reveals a 3-cm mass in the anterior joint space. Arthroscopic surgery with partial synovectomy is performed, and a nodular, encapsulated mass is removed. Microscopic examination of the mass shows synoviocyte-like tumor cells in a hyalinized stroma containing osteoclast-like giant cells and hemosiderin. An antagonist to which of the following growth factors is most useful in treating this lesion?

**Core Concept**
The question tests the student's knowledge of a specific type of tumor that arises from the synovium, a layer of connective tissue that surrounds the joints. This tumor is characterized by the presence of synoviocyte-like cells, osteoclast-like giant cells, and hemosiderin, which are indicative of a hemophilic synovial lesion.

**Why the Correct Answer is Right**
The correct answer is an antagonist to platelet-derived growth factor (PDGF). PDGF is a growth factor that plays a crucial role in the proliferation and migration of synovial fibroblasts, which are the cells that give rise to the tumor in question. The presence of PDGF in the synovial fluid and the tumor tissue promotes the growth and proliferation of the tumor cells. Therefore, an antagonist to PDGF would be useful in treating this lesion by inhibiting the growth and proliferation of the tumor cells.

**Why Each Wrong Option is Incorrect**
**Option A:** VEGF (vascular endothelial growth factor) is a growth factor that promotes angiogenesis, the formation of new blood vessels. While VEGF is involved in the pathogenesis of various types of tumors, it is not directly involved in the growth and proliferation of synovial lesions.

**Option B:** TGF-β (transforming growth factor-beta) is a growth factor that has both tumor-suppressive and tumor-promoting effects, depending on the context. While TGF-β is involved in the regulation of synovial fibroblast growth, it is not the primary growth factor involved in the pathogenesis of synovial lesions.

**Option C:** FGF (fibroblast growth factor) is a growth factor that promotes the growth and proliferation of various types of cells, including fibroblasts and endothelial cells. While FGF is involved in the pathogenesis of various types of tumors, it is not directly involved in the growth and proliferation of synovial lesions.

**Option D:** TNF-α (tumor necrosis factor-alpha) is a cytokine that promotes inflammation and cell death. While TNF-α is involved in the pathogenesis of various inflammatory conditions, it is not directly involved in the growth and proliferation of synovial lesions.

**Clinical Pearl / High-Yield Fact**
Synovial lesions, such as the one described in this question, are often associated with joint pain, reduced range of motion, and a "popping and catching" sensation. The presence of osteoclast-like giant cells and hemosiderin in the tumor tissue is a characteristic feature of these lesions, and an antagonist to PDGF is a useful treatment option.

**Correct Answer:** C.

✓ Correct Answer: C. M-CSF